

## INFORMATION DISCLOSURE STATEMENT

Applicant : Hart et al.  
App. No : 10/538,393  
Filed : June 8, 2005  
For : IN VITRO IMMUNIZATION  
Examiner : Unknown  
Art Unit : 1636

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 10 references to be considered by the Examiner. Also enclosed are 10 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 1/31/07

By: Raymond D. Smith

Raymond D. Smith  
Registration No. 55,634  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/538,393	
	Filing Date	June 8, 2005	
	First Named Inventor	Hart et al.	
	Art Unit	1636	
(Multiple sheets used when necessary)		Examiner	Unknown
SHEET 1 OF 1		Attorney Docket No.	DAV1257.003APC

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	1	International Search Report for International Application No. PCT/AU2003/001647, filed December 9, 2003.	
	2	CHO, H-I et al. 2001 "Generation of cytotoxic T lymphocytes specific for human cytomegalovirus using dendritic cells <i>in vitro</i> " <i>J Immunotherapy</i> 24:242-249.	
	3	HOFFMANN, TK et al. 2000 "Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells" <i>Cancer Research</i> 60:3542-3549.	
	4	ITO, A et al. 2001 "Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells" <i>J Gastroenterology and Hepatology</i> 16:309-316.	
	5	RE, F et al. (November 16, 2002) "Green fluorescent protein (GFP) expression in dendritic cells enhances their immunogenicity and elicits GFP-specific cytotoxic T-cell (CTL) responses in humans" <i>Blood</i> 100(11) pp. Abstract No. 2663, Whole Abstract.	
	6	PEGGS K et al. 2001 "Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions" <i>Blood</i> 97:994-1000.	
	7	PEGGS, K et al. 2002 "Characterization of human cytomegalovirus peptide-specific CD8 <sup>+</sup> T-cell repertoire diversity following <i>in vitro</i> restimulation by antigen-pulsed dendritic cells" <i>Blood</i> 99:213-223.	
	8	PÉREZ-DÍEZ, A. et al. 1998 "Generation of CD8 <sup>+</sup> and CD4 <sup>+</sup> T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene" <i>Cancer Research</i> 58:5305-5309.	
	9	SZMANIA, S. et al. 2001 "Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers" <i>Blood</i> 98:505-512.	
	10	VERFUERTH, S et al. (November 16, 2000) "A versatile culture system for the <i>in vitro</i> expansion of autologous donor-derived cytomegalovirus, Epstein Barr virus and Aspergillus antigen-specific T cells" <i>Blood</i> 96(11, part 1) pp. 27a, Abstract No. 103, Whole Abstract.	

3340214  
012307

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.